drugset / Trial / NCT00368901

STAAR-2 Clinical Study

NCT00368901

Phase 4 Completed 618 enrolled Amgen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the effect of Aranesp on the hemoglobin (Hgb) of CRI subjects who are recombinant human erythropoietin (rHuEPO)-naïve or converting from rHuEPO therapy.

Timeline

Start
2002-01
Primary completion
2004-03
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic Subcutaneous